[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335485-105":59,"doc-detail-335485-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","er-status-of-invasive-ductal-breast-carcinoma-as-a-result-of-regulatory-interactions-between-lysine-deacetylases-kat6a-and-kat6b","ERα status of invasive ductal breast carcinoma as a result of regulatory interactions between lysine deacetylases KAT6A and KAT6B","","Investigates how lysine acetyltransferases KAT6A and KAT6B influence clinical and molecular features of invasive ductal breast carcinoma, focusing on ER-related regulatory interactions. Using immunohistochemistry across IDC and mastopathy cohorts and assessing multiple breast cancer cell lines and mammary epithelial cells at mRNA and protein levels, the study links nuclear KAT6A/B expression with estrogen receptor status. It further shows higher KAT6A cytoplasmic and nuclear levels in IDC versus benign controls, correlates KAT6A/B with ER and PR patterns, and demonstrates that siRNA suppression and KAT6A/B inhibition reduce ER expression, supporting roles in progression and biomarker potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/er-status-of-invasive-ductal-breast-carcinoma-as-a-result-of-regulatory-interactions-between-lysine-deacetylases-kat6a-and-kat6b/335485/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/er-status-of-invasive-ductal-breast-carcinoma-as-a-result-of-regulatory-interactions-between-lysine-deacetylases-kat6a-and-kat6b/335485.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role do KAT6A and KAT6B play in invasive ductal breast carcinoma according to the study?","Question",{"text":112,"@type":113},"The findings suggest that KAT6A and KAT6B are involved in the progression of invasive ductal breast cancer and may serve as diagnostic and prognostic markers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are KAT6A/B levels assessed in patient and cell samples?",{"text":117,"@type":113},"KAT6A/B expression is examined in patient tissue by immunohistochemistry and measured in breast cancer cell lines and mammary epithelial cells at both mRNA and protein levels.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the relationship between KAT6A/B expression and estrogen receptor status?",{"text":121,"@type":113},"Nuclear expression of KAT6A/B correlates with estrogen receptor status, with additional significant correlations between KAT6A and ER/PR and between KAT6B and ER/PR.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335485,1790164562,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nERα status of invasive ductal breast carcinoma as a result of regulatory interactions between lysine deacetylases KAT6A and KAT6B  \nMateuszOlbromski1􀀍, Monika Mrozowska1, Beata Smolarz2, Hanna Romanowicz2, Agnieszka Rusak1 & Aleksandra Piotrowska1  \nBreast cancer (BC) is the leading cause of death among cancer patients worldwide. In 2020, almost 12% of all cancers were diagnosed with BC. Therefore, it is important to search for new potential markers of cancer progression that could be helpful in cancer diagnostics and successful anti-cancer therapies. In this study, we investigated the potential role of the lysine acetyltransferases KAT6A and KAT6B in the outcome of patients with invasive breast carcinoma. The expression profiles of KAT6A/B in 495 cases of IDC and 38 cases of mastopathy (FBD) were examined by immunohistochemistry. KAT6A/B expression was also determined in the breast cancer cell lines MCF-7, BT-474, SK-BR-3, T47D, MDA-MB-231, and MDA-MB-231/BO2, as well as in the human epithelial mammary gland cell line hTERT-HME1 – ME16C, both at the mRNA and protein level. Statistical analysis of the results showed that the nuclear expression of KAT6A/B correlates with the estrogen receptor status: KAT6ANUC vs. ER r =0.2373 and KAT6BNUC vs. ER r =0.1496. Statistical analysis clearly showed that KAT6A cytoplasmic and nuclear expression levels were significantly higher in IDC samples than in FBD samples (IRS 5.297 ± 2.884 vs.  \n2.004 ± 1.072, p \u003C 0.0001; IRS 5.133 ± 4.221 vs. 0.1665 ± 0.4024, p \u003C 0.0001, respectively) . Moreover, we noticed strong correlations between ER and PR status and the nuclear expression of KAT6A and KAT6B (nucKAT6A vs. ER, p = 0.0048; nucKAT6A vs. PR p = 0.0416; nucKAT6B vs. ERp = 0.0306; nucKAT6B vs. PR p = 0.0213). Significantly higher KAT6A and KAT6B expression was found in the ER-positive cell linesT-47D and BT-474, whereas significantly lower expression was observed in the triple-negative cell lines MDA-MB-231 and MDA-MB-231/BO2. The outcomes of small interfering RNA (siRNA)-mediated suppression of KAT6A/B genes revealed that within estrogen receptor (ER) positive and negative cell lines, MCF-7 and MDA-MB-231, attenuation of KAT6A led to concurrent attenuation of KAT6A, whereas suppression of KAT6B resulted in simultaneous attenuation of KAT6A. Furthermore, inhibition of KAT6A/B genes resulted in a reduction in estrogen receptor (ER) mRNA and protein expression levels in MCF-7 and MDA-MMB-231 cell lines. Based on our findings, the lysine acetyltransferases KAT6A and KAT6B may be involved in the progression of invasive ductal breast cancer. Further research on other types of cancer may show that KAT6A and KAT6B could serve as diagnostic and prognostic markers for these types of malignancies.  \nBreast Cancer (BC) is a type of cancer primarily caused by the abnormal and uncontrolled growth of mammary gland cells. Since cancer progression can occur in different types of mammary gland cells, different types of breast cancer can be distinguished1. Breast cancer has been the most common type of malignancy in women1–5. Recent research shows that one out of eight women in the U.S. will develop Invasive Ductal Breast Carcinoma  \n(IDC) during their lifetime. Nearly 300,000 new cases of IDC are expected to be diagnosed in 2021 in the United States alone6,7. Moreover, for the first time BC has overtaken lung cancer as the most common cancer worldwide (nearly 12% of new cases)6,7. More than 19.3 million new cases of BC were diagnosed in 2020 (which represents almost 11.7% of all cancers), with lung cancer ranking second and colorectal cancer third. There are well-known risk factors responsible for breast cancer development, such as tobacco use, low fruit and vegetable consumption, high BMI, alcohol use, and lack of physical activity1,4,5,8–11. The increase in the world population leads to one more observation: by 2040, approximately ","cbCainToJUxzZwNN","https://ap.wps.com/l/cbCainToJUxzZwNN","pdf",2688174,13,"English","# Study objective and clinical relevance\n# Methods and expression profiling\n# Statistical associations with ER/PR\n# Functional suppression by siRNA and inhibition\n# Conclusions and biomarker implications","[{\"question\":\"What role do KAT6A and KAT6B play in invasive ductal breast carcinoma according to the study?\",\"answer\":\"The findings suggest that KAT6A and KAT6B are involved in the progression of invasive ductal breast cancer and may serve as diagnostic and prognostic markers.\"},{\"question\":\"How are KAT6A/B levels assessed in patient and cell samples?\",\"answer\":\"KAT6A/B expression is examined in patient tissue by immunohistochemistry and measured in breast cancer cell lines and mammary epithelial cells at both mRNA and protein levels.\"},{\"question\":\"What is the relationship between KAT6A/B expression and estrogen receptor status?\",\"answer\":\"Nuclear expression of KAT6A/B correlates with estrogen receptor status, with additional significant correlations between KAT6A and ER/PR and between KAT6B and ER/PR.\"}]","ERα status of invasive ductal breast carcinoma as a result of regulatory interactions between lysine deacetylases KAT6A and KAT6B | PDF",1790011121,33]